POSTMENOPAUSAL BMD

绝经后骨密度

• 批准号: 6265509
• 负责人: NORMAN L BELL
• 金额: $ 1.74万
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6265509
• 关键词: alendronate; bone density; clinical research; dosage; drug adverse effect; drug screening /evaluation; female; human subject; human therapy evaluation; longitudinal human study; postmenopause; skeletal disorder chemotherapy

To compare the effects on lumbar spine BMD of 1 year of treatment with alendronate 35 mg once weekly compared to treatment with 5 mg daily in postmenopausal women. To assess the safety and tolerablility of 1 year of treatment with alendronate 35 mg once weekly compared to treatment with 5 mg daily in postmenopausal women. To compare the effects of BMD of the hip and total body of 1 year treatment with alendronate 35 mg once weekly with those of 5 mg daily in postmenopausal women. To assess the effect of 1 and 2 years of treatment with alendronate 35 mg once weekly compared to treatment with alendronate 5 mg daily on the rate of bone turnover as assessed by biochemical markers (NTx and BSAP) in postmenopausal women. To assess the effect of 2 years of treatment with alendronate 35 mg once weekly compared to treatment with alendronate 5 mg daily in postmenopausal women on (a) BMD at the lumbar spine, hip, and total body, and (b) safety and tolerability.

比较绝经后妇女每周一次阿仑膦酸钠35 mg与每日5 mg治疗1年对腰椎BMD的影响。 评估绝经后女性接受阿仑膦酸钠35 mg每周一次治疗1年与每日5 mg治疗相比的安全性和耐受性。 比较阿仑膦酸钠35 mg每周1次与5 mg每日1次治疗1年对绝经后妇女髋部和全身骨密度的影响。 评估阿仑膦酸钠35 mg每周一次治疗1年和2年与阿仑膦酸钠5 mg每日一次治疗相比对绝经后女性骨转换率的影响，通过生化标志物（NTx和BSAP）进行评估。在绝经后女性中评估阿仑膦酸钠35 mg每周一次治疗2年与阿仑膦酸钠5 mg每日一次治疗相比对（a）腰椎、髋关节和全身BMD的影响，以及（B）安全性和耐受性的影响。